Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
- PMID: 25360116
- PMCID: PMC4197894
- DOI: 10.3389/fphys.2014.00391
Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
Abstract
Phosphoinositide 3-kinases (PI3Ks) regulate several cellular functions that are critical for cancer progression and development, including cell survival, proliferation and migration. Three classes of PI3Ks exist with the class I PI3K encompassing four isoforms of the catalytic subunit known as p110α, p110β, p110γ, and p110δ. Although for many years attention has been mainly focused on p110α recent evidence supports the conclusion that p110β, p110γ, and p110δ can also have a role in cancer. Amongst these, accumulating evidence now indicates that p110γ is involved in several cellular processes associated with cancer and indeed this specific isoform has emerged as a novel important player in cancer progression. Studies from our laboratory have identified a specific overexpression of p110γ in human pancreatic ductal adenocarcinoma (PDAC) and in hepatocellular carcinoma (HCC) tissues compared to their normal counterparts. Our data have further established that selective inhibition of p110γ is able to block PDAC and HCC cell proliferation, strongly suggesting that pharmacological inhibition of this enzyme can directly affect growth of these tumors. Furthermore, increasing evidence suggests that p110γ plays also a key role in the interactions between cancer cells and tumor microenvironment and in particular in tumor-associated immune response. It has also been reported that p110γ can regulate invasion of myeloid cells into tumors and tumor angiogenesis. Finally p110γ has also been directly involved in regulation of cancer cell migration. Taken together these data indicate that p110γ plays multiple roles in regulation of several processes that are critical for tumor progression and metastasis. This review will discuss the role of p110γ in gastrointestinal tumor development and progression and how targeting this enzyme might represent a way to target very aggressive tumors such as pancreatic and liver cancer on multiple fronts.
Keywords: HCC; PDAC; angiogenesis; cancer; inflammation; metastasis; p110γ; phosphoinositide 3-kinase.
Figures
Similar articles
-
Ligand-selective signal transduction by two endogenous GnRH isoforms involves biased activation of the class I PI3K catalytic subunits p110β, p110γ, and p110δ in pituitary gonadotropes and somatotropes.Endocrinology. 2015 Jan;156(1):218-30. doi: 10.1210/en.2014-1640. Endocrinology. 2015. PMID: 25343277
-
The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8292-7. doi: 10.1073/pnas.0707761105. Epub 2008 Jun 10. Proc Natl Acad Sci U S A. 2008. PMID: 18544649 Free PMC article.
-
Activity of any class IA PI3K isoform can sustain cell proliferation and survival.Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11381-6. doi: 10.1073/pnas.0906461107. Epub 2010 Jun 7. Proc Natl Acad Sci U S A. 2010. PMID: 20534549 Free PMC article.
-
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.Recent Pat DNA Gene Seq. 2007;1(1):9-23. doi: 10.2174/187221507779814461. Recent Pat DNA Gene Seq. 2007. PMID: 19075915 Review.
-
Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.Adv Biol Regul. 2020 Jan;75:100657. doi: 10.1016/j.jbior.2019.100657. Epub 2019 Sep 28. Adv Biol Regul. 2020. PMID: 31611073 Review.
Cited by
-
High expression of the phosphoinositide 3-kinase p11γ isoform can predict poor prognosis of non-small cell lung cancer.Histol Histopathol. 2022 Dec;37(12):1177-1184. doi: 10.14670/HH-18-480. Epub 2022 Jun 8. Histol Histopathol. 2022. PMID: 35673779
-
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.Clin Cancer Res. 2022 Jun 1;28(11):2257-2269. doi: 10.1158/1078-0432.CCR-21-3087. Clin Cancer Res. 2022. PMID: 35247924 Free PMC article. Clinical Trial.
-
Prediction of immunotherapy response using mutations to cancer protein assemblies.Sci Adv. 2024 Sep 20;10(38):eado9746. doi: 10.1126/sciadv.ado9746. Epub 2024 Sep 20. Sci Adv. 2024. PMID: 39303028 Free PMC article.
-
Function, Regulation and Biological Roles of PI3Kγ Variants.Biomolecules. 2019 Aug 30;9(9):427. doi: 10.3390/biom9090427. Biomolecules. 2019. PMID: 31480354 Free PMC article. Review.
-
The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.Int J Mol Sci. 2022 Apr 13;23(8):4295. doi: 10.3390/ijms23084295. Int J Mol Sci. 2022. PMID: 35457111 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources